Volume | 66,521 |
|
|||||
News | - | ||||||
Day High | 0.44 | Low High |
|||||
Day Low | 0.4111 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Theriva Biologics Inc | TOVX | AMEX | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.4351 | 0.4111 | 0.44 | 0.4152 | 0.448 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
342 | 66,521 | $ 0.4234414 | $ 28,168 | - | 0.1972 - 1.20 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:20:00 | 34 | $ 0.4199 | USD |
Theriva Biologics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
17.38M | 17.04M | - | 0 | -18.35M | -1.08 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Theriva Biologics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TOVX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.45 | 0.46 | 0.4111 | 0.4413957 | 27,208 | -0.04 | -8.89% |
1 Month | 0.4801 | 0.5446 | 0.4111 | 0.4661006 | 53,437 | -0.0701 | -14.60% |
3 Months | 0.415 | 0.6845 | 0.41 | 0.5342167 | 99,927 | -0.005 | -1.20% |
6 Months | 0.485 | 0.6845 | 0.1972 | 0.5081309 | 77,640 | -0.075 | -15.46% |
1 Year | 0.71 | 1.20 | 0.1972 | 0.826347 | 231,252 | -0.30 | -42.25% |
3 Years | 0.80 | 1.26 | 0.1972 | 0.816938 | 176,604 | -0.39 | -48.75% |
5 Years | 0.80 | 1.26 | 0.1972 | 0.816938 | 176,604 | -0.39 | -48.75% |
Theriva Biologics Description
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11, leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. |